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More than 85% of advanced breast cancer patients
suffer from metastatic bone lesions, yet the mecha-
nisms that facilitate these metastases remain poorly
understood. Recent studies suggest that tumor-
derived factors initiate changes within the tumor
microenvironment to facilitate metastasis. However,
whether stromal-initiated changes are sufficient to
drive increased metastasis in the bone remains an
open question. Thus, we developed a model to
induce reactive senescent osteoblasts and found
that they increased breast cancer colonization of
the bone. Analysis of senescent osteoblasts revealed
that they failed to mineralize bone matrix and
increased local osteoclastogenesis, the latter pro-
cess being driven by the senescence-associated
secretory phenotype factor, IL-6. Neutralization of
IL-6 was sufficient to limit senescence-induced
osteoclastogenesis and tumor cell localization to
bone, thereby reducing tumor burden. Together,
these data suggest that a reactive stromal compart-
ment can condition the niche, in the absence of tu-
mor-derived signals, to facilitate metastatic tumor
growth in the bone.
INTRODUCTION
Cancer is an ecological disease that emerges from a dynamic
interplay between incipient tumor cells and their surrounding
stromal environment (Hanahan and Weinberg, 2011). Stromal
changes not only impact primary tumor development, but also
convert future metastatic sites into a fertile environment (niche)
that supports the survival and outgrowth of tumor cells (Psaila82 Cell Reports 14, 82–92, January 5, 2016 ª2016 The Authorsand Lyden, 2009; Sceneay et al., 2013 and references therein).
An outstanding question that remains is what drives tumor cell
seeding and growth within distal sites and can these changes
be inhibited or reverted? This question has led to a persuasive
body of work demonstrating that primary tumor cells can release
factors systemically that mobilize bone-marrow-derived cells to
distal target organs to condition the pre-metastatic site (Hirat-
suka et al., 2002 and references found in Sceneay et al., 2013).
In addition to soluble factors, exosomes released from primary
tumor cells, hypoxia within the primary tumor, and primary tu-
mor-driven reductions in immune surveillance can alsomodulate
the pre-metastatic niche and increase metastasis to distal or-
gans (Psaila and Lyden, 2009; Sceneay et al., 2012, 2013 and
references therein). However, whether stromal cells naturally
residing in the bone are sufficient to initiate changes that facili-
tate subsequent tumor cell seeding and growth in the absence
of systemic signals generated from primary tumor cells has not
been explored.
RESULTS
Senescent Osteoblasts Drive Increased Breast Cancer
Growth in the Bone
To determine if stromal changes arising within the bone in the
absence of signals emanating from a primary tumor are sufficient
to foster tumor cell colonization, we turned our attention to the
putative role that senescent stromal cells play in the process.
Indeed, senescent fibroblasts secrete a plethora of factors
(referred to as the senescence-associated secretory phenotype,
SASP) that impact every step in the tumorigenic process (Coppe´
et al., 2008; Krtolica et al., 2001; Parrinello et al., 2005). As such,
senescent cells recapitulate the activities of reactive stromal
cells including cancer-associated fibroblasts (CAFs), which are
known to impact cancer initiation and progression (Bavik et al.,
2006; Olumi et al., 1999). Thus, we postulated that senescent
cells create a pro-tumorigenic microenvironment that favors
Figure 1. Transgene Activation in Osteo-
blasts Results in Senescence and SASP
Expression
(A) Characterization of transgene activation in
FASSTmice. Representative immunofluorescence
(IF) staining of frozen bone sections obtained from
littermate (LM) control or FASST mice was per-
formed with anti-GFP (green) and anti-osteocalcin
(OCN) (red) antibodies. IF staining revealedmosaic
activation with variable penetrance of the p27Kip1
transgene (GFP+) within OCN (+) osteoblasts
(see Figure S1A). Scale bar, 100 mm; magnification
103; inset, 203 (n = 4).
(B) Quantification of transgene activation (GFP+) in
five bone sections from four different FASST mice
shows a wide variation in transgene activation.
GFP-positive counts from the same mouse are
coded as a single color.
(C) Representative SA-b-Gal staining in FASST
versus littermate control bone sections. Quantifi-
cation of SA-b-Gal staining in littermate control
(LM) or FASST mice. Senescent bone-lining cells
are denoted by a black arrowhead. Data are pre-
sented as a percentage of total bone-lining cells.
Scale bar, 100 mm (n = 3) (*SEM, p < 0.05, two-
tailed, Student’s t test).
(D) Representative staining of IL-6 (red) SASP
expression in the bones of FASST mice revealed
robust activation in GFP+ (green), senescent os-
teoblasts. No GFP expression was observed in the
littermate (LM) mice, and no significant IL-6
expression was noted in the LM controls. Scale
bar, 100 mm, magnification 103; inset, 403 (n = 4).
Secondary antibody panel with existing LM and
FASST IL-6 stains can be found in Figure S1B for
reference.
(E) Quantification of IL-6 expression in GFP+ os-
teoblasts from bone sections of FASST mice (n = 4
mice, five bone sections each). IL-6 was ex-
pressed in 75% of GFP-positive cells, while
25% of GFP-positive cells had no detectable
IL-6 expression.the seeding and/or outgrowth of tumor cells and that this could
occur independent of a distantly located primary tumor. To test
this, we developed a conditional mouse model that allowed us
to spatially and temporally control senescence induction within
the mesenchymal compartment. In doing so, we hypothesized
that osteoblasts, like closely related fibroblasts, undergo a
senescence response that echoes that previously observed in
the latter cell type. Our ‘‘FASST’’ (fibroblasts accelerate stro-
mal-supported tumorigenesis) model uses a stromal-specific,
estrogen-responsive Cre recombinase (Cre-ERT2) to create
senescent osteoblasts in mice by inducing expression of the
cell-cycle inhibitor, p27Kip1. We chose to use p27Kip1 in our
model because it faithfully recapitulated the senescent pheno-
type observed in human cells. Indeed, expression of p27Kip1 is
sufficient to induce senescence (Alexander and Hinds, 2001)
and robust pro-tumorigenic SASP expression in fibroblasts
from these mice (unpublished data). Thus, p27Kip1 is an impor-
tant tool that we have utilized to recapitulate the physiology
observed in human tissue. To restrict expression to the mesen-chymal compartment, mice carrying the Cre-ERT2 transgene
driven by the pro-alpha 2(I)collagen promoter (Zheng et al.,
2002) were mated to mice that conditionally express p27Kip1
and a lineage tracing IRES GFP allele from the ROSA26 locus
(ROSAlox-stop-lox-p27Kip1IRESGFP) (Lavine et al., 2008). Cre
recombinase was activated in mice 4 weeks of age and GFP
expression and induction of senescence markers were moni-
tored within the bone. To control for any unanticipated effects
of tamoxifen, all mice (Cre+ and Cre–) received tamoxifen.
Following Cre activation, we observed mosaic induction of the
p27Kip1 transgene (GFP+ cells) within osteoblasts in murine
bones (Figure 1A) with variable penetrance. Indeed, in four ani-
mals we found that 17%–64% of osteocalcin (OCN)-positive os-
teoblasts expressed the p27Kip1 transgene (Figures 1B and S1A).
Having established that transgene activation occurred in oste-
oblasts (Figures 1A and 1B), we stained bone sections from
FASST mice or littermate controls for senescence associated
b-galactosidase (SA-b-Gal). p27Kip1 transgene activation led to
a mosaic yet significant induction of senescence within theCell Reports 14, 82–92, January 5, 2016 ª2016 The Authors 83
Figure 2. Senescent Stromal Cells Increase Bone Metastasis
(A) FASSTmice display increased bone tumor burden. Isogenic breast cancer,
NT2.5luc cells were introduced into littermate control (LM) or FASST mice by
left intracardiac injection (IC). Four weeks later, mice were sacrificed, and their
leg bones were imaged ex vivo. Significantly higher tumor burden was
observed in FASST mice compared to littermate controls (n > 20). SEM, *p <
0.05, unpaired Student’s t test with Welch’s correction. Importantly, the dis-
tribution of tumor burdens corresponded with the variable activation of
senescence noted in FASST mice.
(B) Tumor morphology was assessed in littermate control (LM) versus FASST
mice. Tumors in bone sections were stained with H&E, and no gross
morphological differences were noted. Scale bar, 100 mm.FASST bone (Figure 1C). Importantly, the increase in SA-b-Gal-
positive cells was limited to bone-lining cells whose location
suggested that they were osteoblasts (inset in Figure 1C). To
determine if the activation of senescence occurred in GFP+ oste-
oblasts, we co-stained bone sections from FASST mice for GFP
and interleukin-6 (IL-6), a well-characterized SASP factor readily
expressed in senescent human and mouse fibroblasts (Coppe´
et al., 2008, 2010). While lower expression of IL-6 was noted
in the littermate control animals, we found that 75.2% of GFP-
positive cells expressed increased levels of IL-6 in FASST
bones (Figures 1D, 1E, S1B, and S1C). Hence, in this respect
the osteoblasts recapitulated the well-documented senescence
behavior of fibroblasts.
Breast cancer cells frequently metastasize to the bone (Co-
leman and Rubens, 1987); thus, we next asked if the presence
of senescent osteoblasts were sufficient to support tumor cell
recruitment and growth. Because spontaneous models of
breast cancer metastasis to the bone do not form overt le-
sions, we utilized intracardiac (IC) injection to assess the
impact of senescent osteoblasts on tumor cell seeding and
metastatic tumor burden within the bone. Isogenic NT2.5 mu-
rine breast cancer cells (Reilly et al., 2000) stably expressing
firefly luciferase (NT2.5luc) were IC injected into FASST mice
or littermate controls. Given the small number of total senes-
cent cells present in the bones of our animals and our goal
to determine how senescent stromal cells impact tumor cell
colonization and growth, we chose to inject only 10,000 tumor
cells, which resulted in a low tumor cell burden in bones. Four
weeks after injection, mice were sacrificed and tumor burden
was measured in the femur and tibia bones by ex vivo biolumi-
nescent imaging. Strikingly, there was significantly higher tu-
mor burden in bones obtained from FASST mice compared
to littermate controls (Figures 2A and 2B). While we cannot ac-84 Cell Reports 14, 82–92, January 5, 2016 ª2016 The Authorscess the degree of GFP activation at endpoint in our mice
because the vast majority of GFP+ cells are no longer detect-
able (Figures S1D–S1F), these data are inline with the variable
degree of senescence activation we observe in our model.
Indeed, as we anticipated, given the variable penetrance of
transgene activation in our model, analyses of tumor burdens
in individual animals revealed a similar distribution when
compared to the degree of GFP activation in FASST mice (Fig-
ures 1B and S1A). Together, these data suggest stochastic
accumulation of senescent osteoblasts in the bone is sufficient
to create a hospitable niche in the absence of signals from pri-
mary tumors.
Senescent Osteoblasts Increase Osteoclastogenesis
To establish how senescent osteoblasts increase bone meta-
stasis, we next isolated osteoblasts (OCN-positive cells)
(Figure S2A) from untreated FASST mice and analyzed how
senescence impacted their function. To induce senescence
in vitro, we treated FASST osteoblasts ex vivo with tamoxifen.
In contrast to TAM treatment of non-Cre-ERT2 expressing oste-
oblasts (Figure S2B) and transgenic osteoblasts treated with
vehicle alone, tamoxifen treatment of transgenic osteoblasts
induced an enlarged, flattened, senescence-like morphology
and growth arrest (Figures 3A and S2C). As expected, growth
arrest correlated with robust SA-b-Gal staining and a significant
increase in the well-characterized SASP factor IL-6 in tamox-
ifen-treated FASST osteoblasts, relative to vehicle-treated os-
teoblasts (Figures 3A, S2D, and S2E). SASP is characterized
by expression of a wide variety of inflammatory cytokines,
growth factors, and extracellular matrix remodeling enzymes.
While each of these categories is expressed in cells undergoing
senescence, the exact factors vary depending on the cell of
origin and the tissue under scrutiny (Coppe´ et al., 2008; Kuil-
man et al., 2008; Rodier and Campisi, 2011; Ruhland et al.,
2015). Because cell-cycle inhibitors including p16IN4a and
p21 do not induce SASP (Coppe´ et al., 2011), we wanted to
ensure that p27Kip1induced SASP. Analysis of our senescent
osteoblasts revealed that in addition to IL-6, sFRP, and Notch3
were robustly induced (Figure S2E). Importantly, we found that
bleomycin treatment, which can activate premature stress
induced senescence (SIPS), also led to increased expression
of IL-6, sFRP, and Notch3 (Figure S2F). Further, analysis of
murine fibroblasts ectopically expressing p27Kip1 revealed
that they too underwent robust senescence as evidenced by
SA-b-Gal expression and expressed numerous inflammatory
cytokines consistent with SASP described in other fibroblasts
(unpublished data). Given the individual factors that contribute
to the SASP is dependent on the cell of origin, our data indi-
cated that p27Kip1 expression is sufficient to induce senes-
cence and SASP expression in osteoblasts.
To determine how senescence affected osteoblast func-
tion, we first examined expression of several osteoblast
markers that are indicative of osteogenic function. When
grown in osteogenic medium (OM), senescent osteoblasts
displayed reduced levels of ALP mRNA compared to nonse-
nescent osteoblasts (Figure 3B). Furthermore, senescent
osteoblasts displayed less ALP protein expression and alizarin
red S staining than vehicle-treated osteoblasts (Figure 3C).
Figure 3. Senescence Abrogates Osteo-
blast Function and Drives Osteoclasto-
genesis
(A) Primary osteoblasts were obtained from the
femurs of 6-week-old FASST mice. To activate the
p27Kip1 transgene and induce senescence, FASST
osteoblasts were treated with 10 mM tamoxifen
(4-OHT) for 3 days. SA-b-Gal staining was carried
out on 4-OHT or vehicle (veh)-treated osteoblasts
on day 3. 4-OHT treatment resulted in a significant
increase in enlarged, flattened cells that stained
positive for SA-b-Gal (blue) compared to vehicle-
treated cells (upper-right panel); scale bar, 200 mm
(*p < 0.05, two-tailed, Student’s t test. one of three
representative experiments is shown). The induc-
tion of the senescence associated secretory
phenotype (SASP) factor IL-6 was also quantitated
RT-PCR (lower-right panel). Senescent osteo-
blasts expressed significantly more IL-6 mRNA
compared to vehicle-treated cells (SEM, *p < 0.05,
two-tailed, Student’s t test; one of three repre-
sentative experiments is shown).
(B) qRT-PCR expression of alkaline phosphatase
(ALP) in vehicle (veh) versus 4-OHT-treated oste-
oblasts grown in basic culture medium (CM)
versus osteogenic medium (OM). Senescent os-
teoblasts displayed a dramatic reduction in ALP
mRNA levels when grown in osteogenic medium
(SEM, *p < 0.05, two-tailed, Student’s t test; one of
two representative experiments is shown).
(C) ALP and alizarin red S staining in senescent
versus non-senescent osteoblasts. FASST osteo-
blasts were treated with vehicle or 4-OHT for
3 days and then plated in basic culture medium (–)
or osteogenic medium (+) for 7 or 21 additional
days. On day 7 ALP expression was assessed
(upper panel, one of four representative experi-
ments is shown), and on day 21 mineralization
capacity was assessed by staining with alizarin red
S (lower panel, one of three representative exper-
iments is shown). 4-OHT-treated osteoblasts dis-
played a robust reduction of both ALP expression
and mineralization capabilities.
(D) Senescent osteoblasts increase osteoclasto-
genesis. As shown on the timeline, osteoblasts
were treatedwith vehicle (veh) or 4-OHT for 3 days.
4-OHT was then removed from the culture
medium, and, on day 12, after robust activation of senescence (data not shown) bone marrow macrophages were plated on non-senescent versus senescent
osteoblasts, and osteoclastogenesis was determined by TRAP staining on day 16. Representative pictographs are shown; scale bar, 200 mm. TRAP-positive
osteoclasts (TRAP+OC) were counted and data are displayed as TRAP+OC/field of view (TRAP+OC/FOV) (SEM, *p < 0.05, two-tailed, Student’s t test; one of
three representative experiments is shown). Because we noted that osteoclast precursor numbers were similar in co-cultures containing non-senescent and
senescent osteoblasts (data not shown), this increase is due to increased osteoclast differentiation.When we used a second conditional genetic mouse model in
which senescence was induced by loss of the telomere-bind-
ing protein TRF2 (Denchi and de Lange, 2007), we observed
the same phenotypes (Figures S3A–S3G). Together, these
data indicate that senescent osteoblasts have significantly
impaired mineralization capacity, regardless of how senes-
cence is induced.
Increased osteoclastogenesis can contribute to tumor cell
growth in the bone (Weilbaecher et al., 2011), and osteoblasts
play an important role in regulating osteoclastogenesis (Long,
2012). Thus, we askedwhether senescent osteoblasts increased
osteoclastogenesis by co-culturing senescent or non-senescentosteoblasts with normal bone-marrow-derived macrophages.
Tartrate-resistant acid phosphatase (TRAP) staining revealed
that non-senescent osteoblasts produced very few osteoclasts
(less than five per field of view), while senescent osteoblasts
stimulated a 4-fold increase in osteoclast formation (Figure 3D).
Similar results were observed when senescence was induced by
loss of TRF2 (Figures S3H and S3I).
Senescent Osteoblasts Increase Tumor Cell Seeding
and Metastatic Tumor Burden in the Bone
To determine if senescent osteoblasts altered the bone micro-
environment, we carried out histomorphometric analysis andCell Reports 14, 82–92, January 5, 2016 ª2016 The Authors 85
Figure 4. Senescent Osteoblasts Increase
Local Osteoclastogenesis
(A) Osteoclast surface to bone surface area was
assessed by TRAP staining. Representative im-
ages of bone sections from 6-week-old littermate
(LM) control or FASST mice are shown and oste-
oclasts are indicated by red, TRAP+ staining and
nuclei are counterstained with hematoxylin. For
these analyses, TRAP+ cells were quantitated in
the tibia near the growth plate using the Bioquant
software. Scale bar, 100 mm (n = 4).
(B) Quantification of osteoclast surface area (Oc S)
per bone surface (BS) was carried out on bone
sections obtained from 6-week-old littermate (LM)
or FASST mice (n = 4, SEM, *p < 0.05, two-tailed,
Student’s t test).
(C) Representative bone sections from 6-week-old
FASST mice were co-stained with antibodies
against GFP (green), OCN (red), and ELF97 TRAP
(blue). Scale bar, 100 mm.
(D) Definition of bining distances for computational
spatial analyses that were overlaid on the image
presented in (C). The lines depict (1) cyan line
outlines the osteoclast; (2) thick line = 200 units of
distance (pixels); and (3) dashed line = 100 units of
distance (pixels). Scale bar, 100 mm.
(E) Computational spatial analysis of bone
sections from FASST mice show increased
osteoclastogenesis within 50 units of senescent
osteoblasts (within the cyan line in D). Statistical
analysis of the frequency of senescent versus non-
senescent osteoblasts encountering an osteo-
clast. Data demonstrate a higher association of
osteoclasts is observed around senescent osteo-
blasts and this associated falls off with distance
(n = 3, SEM, *p < 0.05, two-sidedWilcoxon signed-
rank test).
(F) Distribution of osteoclasts ‘‘within’’ 50 units is
shown from data in (E). As we noted in Figure 1, the
distribution of osteoclasts increasing near senes-
cent osteoblasts corresponds with the variable
activation of senescence noted in FASSTmice (n =
3, SEM, *p < 0.05, two-sided Wilcoxon signed-
rank test).found that senescent osteoblasts in FASST mice significantly
increased the surface area of the bone covered by osteoclasts
compared to total bone surface area (OC S/BS) by nearly
2-fold when compared to littermate controls (Figures 4A and
4B). Despite this increase, we failed to detect systemic evi-
dence of bone turnover (e.g., increases in serum CTX levels
or morphological bone changes by mCT, data not shown),
leading us to postulate that the mosaic appearance of senes-
cent osteoblasts in FASST mice create localized changes in
bone homeostasis. This disruption would take the form of
SASP-driven increases in local osteoclastogenesis and subse-
quent release of bone-bound latent growth factors that are
known to fuel tumor cell growth in the bone (Weilbaecher
et al., 2011). Further, if these local changes were restricted
to areas directly surrounding senescent osteoblasts, then
they would be sufficient to create focal niches that would pro-
mote tumor cell colonization. If true, we would predict that
osteoclastogenesis would be enhanced around senescent os-
teoblasts in FASST mice.86 Cell Reports 14, 82–92, January 5, 2016 ª2016 The AuthorsTo test this, we asked whether osteoclasts preferentially
localize to areas adjacent to senescent versus non-senescent
osteoblasts. Bone sections from FASST mice were stained
simultaneously with antibodies against OCN to identify osteo-
blasts, GFP to identify senescent cells, and TRAP to identify os-
teoclasts (Figure 4C). We then determined the frequency of
TRAP-positive osteoclasts arising in the vicinity of GFP/OCN-
double-positive (senescent) osteoblasts versus GFP-negative,
OCN-positive (non-senescent) osteoblasts (Figure 4D). Using
statistical methods designed to analyze spatial processes (Ro-
dan and Martin, 1981), we found as expected that osteoclasts
localized near osteoblasts more frequently than chance would
predict. This was demonstrated by ratios of observed to
random chance being greater than 1 (dotted line on graph, Fig-
ure 4E). Strikingly, this association was significantly (p < 0.05)
higher around GFP-positive, senescent osteoblasts (relative
probability: 7.5) compared to non-senescent osteoblasts (rela-
tive probability: 4.3) when we examined osteoblasts ‘‘within’’
the osteoclast area (i.e., within the cyan lines, which marks
Figure 5. Senescent Osteoblasts Drive Tu-
mor Cell Seeding
(A) Immunofluorescent staining to detect tumor
cells and senescent osteoblasts in FASST mice.
For these analyses, sections from the femurs of 6-
week-old FASST mice were obtained 3 days after
NT2.5luc cells were introduced intracardically.
Femurs were completely sectioned and EpCAM
staining (red) was used to identify tumor cells, and
anti-GFP staining (green) was used to identify se-
nescent osteoblasts. Representative images are
shown; scale bar, 1 mm, red inset is 203, and
white inset is 603 (n = 3 femurs). Total number of
tumor cells analyzed was 32, 16, and seven from
bones from three different mice). Stains using a
secondary antibody alone stain and FASST mice
with no tumor cells can be found in Figure S4A.
(B) Computational spatial analysis of tumor cell
localization. The image shown in (A) was masked
as follows to determine tumor cell localization. The
growth plate, which was the region of the femur
where greater than 90% of tumor cells were
localized, was masked to facilitate statistical
analysis. Tumor cells were coded as red stars, and
senescent osteoblasts were coded as green dots.
Scale bar, 1 mm.
(C) The likelihood that a tumor cell (gray dots)
would encounter a senescent osteoblast by
chance (dotted line at 0) versus the observed fre-
quency was calculated for each osteoblast.
Osteoblast locations were sampled instead of tu-
mor cell locations to minimize edge effects asso-
ciated with tumor cells located near the border of
the region of interest. Following the sampling, the
mean, SD, median, and 95% confidence interval
were computed. To better visualize the difference
between the observed and expected distance
distributions, the ratio of the observed and ex-
pected median distance functions was taken.
Where this plot is greater than 1, the distance to
the nth senescent osteoblast from a tumor cell was
larger than expected, favoring segregation of the
two cell populations. Where this plot is less than 1,
the distance from a tumor cell to the nth nearest senescent osteoblast is smaller than expected, thus favoring association of the two populations. To allow for
combination of data across multiple samples and mice, a normalized difference (also referred to as effect size) curve was computed. The difference between the
observed distance and mean difference for the nth nearest osteoblast was taken and normalized by sampling SD. The resulting curve provides a measure of how
many SDs away from the random mean the observed results lie. To allow the graph to show positive numbers for association, the negative of the normalized
difference is plotted. p values are found in Figure S5.the border of the osteoclast, Figure 4F), indicating the increased
presence of osteoclasts around GFP-positive senescent osteo-
blasts in vivo.
Next, we wondered whether senescent osteoblasts would
also create a favorable niche for tumor cell seeding, thereby ex-
plaining the increased tumor growth observed in the bones of
FASST mice. To directly test whether tumor cells traffic to
regions surrounding senescent osteoblasts (observed in Fig-
ure 4C), we injected NT2.5luc cells into FASST mice and sacri-
ficed mice 3 days later, a time point long enough to permit local-
ization to distant tissue sites but before overt tumors are
observable. To identify NT2.5luc tumor cells, we stained bone
sections of FASSTmice with an antibody against EpCAM, a spe-
cific marker of epithelial cells not found in the normal bone and,
as before, used an antibody against GFP to identify senescentosteoblasts (Figures 5A and S4A). We then determined whether
EpCAM-positive tumor cells localized near senescent, GFP-pos-
itive osteoblasts more frequently than chance would predict. To
establish the degree of tumor cell localization, we utilized a
similar computational approach as described above, and the
data are presented as normalized to the chance that there is as-
sociation (greater than one) or repulsion (less than one). These
analyses revealed that tumor cells localized around senescent
osteoblasts (Figures 5B, 5C, S4A, and S5) significantly more
often than would be predicted by chance. Further, this associa-
tion was robust because we found that, when we excluded the
trabecular bone regions from our analysis, an area where tumor
cells cannot localize too, it did not impact our findings (Fig-
ure S4B). Thus, our data suggest that senescent osteoblasts
locally increase tumor cell seeding and/or outgrowth.Cell Reports 14, 82–92, January 5, 2016 ª2016 The Authors 87
While the mechanisms that drive cancer cells to the bone
remain poorly understood, it is known that osteoblast-derived
CXCL12 can attract tumor cells (Taichman et al., 2002). Analyses
of senescent and non-senescent osteoblasts failed to show a
difference in CXCL12 expression (data not shown), suggesting
that other senescent-derived factors were responsible for the
increased tumor cell seeding and growth in the bone. Our model
suggests that the stochastic appearance of senescent osteo-
blasts in the bones of FASSTmice drive local increases in osteo-
clastogenesis, which creates a rich pro-metastatic milieu that
facilitates tumor cell seeding and/or outgrowth. Thus, we hy-
pothesized that senescence-induced osteoclastogenesis is a
main driver of tumor seeding. Because we failed to observe
changes in the osteoclastogenic factors, RANKL and M-CSF
(data not shown), we turned our attention to the SASP factor
IL-6, which can increase osteoclast differentiation (Udagawa
et al., 1995), plays an important role in metastasis (Tawara
et al., 2011), and is highly upregulated in senescent osteoblasts
(Figures 1D, 3A, and S3S). Indeed, many cancer cells express
IL-6, while others stimulate surrounding stromal cells to secrete
high levels of IL-6 that drive increases in osteoclastogenesis and
tumor cell adaptation and growth in the bone (Tawara et al., 2011
and references therein).
Senescent-Derived IL-6 Drives Osteoclastogenesis and
Tumor Cell Growth in the Bone
To determine if senescence-derived IL-6 was responsible for the
increased osteoclastogenesis observed in FASST mice, we uti-
lized an IL-6-neutralizing antibody. Because IL-6 is required to
maintain the senescent phenotype in some settings, we first
confirmed that IL-6 neutralization had no impact on the mainte-
nance of senescence or expression of SASP factors in senes-
cent osteoblasts (data not shown and Figures S6A–S6D). Next,
we carried out an ex vivo osteoclastogenesis assay. As ex-
pected, the presence of senescent osteoblasts significantly
increased the number and size of osteoclasts; however, this in-
crease was completely abrogated in the presence of an IL-6-
neutralizing antibody (Figure 6A). This finding indicated that
increased osteoclastogenesis is driven by high levels of senes-
cent-derived IL-6.
Given our in vitro findings, we next asked if neutralization of se-
nescent-derived IL-6 reduced tumor cell colonization of the bone
in FASST mice. FASST or littermate mice were treated with con-
trol immunoglobulin G (IgG) or anti-IL-6 IgG, and NT2.5luc tumor
cell growth in the bone was assessed following IC injection. As
expected, control IgG recapitulated the increased bone coloni-
zation and tumor cell outgrowth observed in FASST mice
compared to littermate controls. In contrast, treatment with
anti-IL-6 led to a striking reduction in tumor burden in the bones
of FASST mice that otherwise exhibited significantly higher tu-
mor burden than littermate controls. Given the importance of
the osteoblastic niche and putative role of IL-6 in bone metas-
tasis, it was not surprising that we also noted that IL-6 neutraliza-
tion reduced tumor cell growth in control animals (reduced by
7.3-fold in control and 29.9-fold in FASST mice, p < 0.05, Fig-
ure 6B). This finding combined with the tumor cell seeding
data (Figure 5) bolsters our hypothesis that senescent osteo-
blasts increase the amount of productive seeding area within88 Cell Reports 14, 82–92, January 5, 2016 ª2016 The Authorsthe bone. In fact, control mice clearly develop tumors within
the bone, indicating that they are proficient in supporting tumor
cell seeding and/or outgrowth. Thus, our data suggest that the
activation of senescent osteoblasts in the FASSTmice increases
the regions within the bone that are capable of supporting tumor
cell seeding and growth.
The significant loss in tumor growth within the bone observed
in FASST mice following IL-6 antibody treatment raised the
important question of how neutralization of IL-6 led to reduced
tumor cell growth. IL-6 is mitogenic in many settings (Schafer
and Brugge, 2007 and references therein), and thus senes-
cence-associated IL-6 could directly stimulate the growth of tu-
mor cells. This raised the possibility that IL-6 neutralization
directly impacted tumor cell growth in our model. To test this
possibility, conditioned medium was isolated from non-senes-
cent and senescent osteoblasts and was added to cultures of
NT2.5luc cells. As expected, senescent osteoblast-conditioned
medium stimulated the growth of NT2.5luc breast cancer cells
40-fold over the growth observed in the presence of conditioned
medium obtained from non-senescent osteoblasts (Figure 6C).
We next asked whether this increased growth was due to IL-6
by culturing NT2.5luc cells in senescent osteoblast-conditioned
medium with an IL-6-neutralizing antibody. We found that
neutralization of IL-6 had no impact on the increased growth of
NT2.5luc cells observed in the presence of senescent-condi-
tioned medium, indicating that the stimulation of NT2.5luc cell
growth by senescent-conditioned medium occurs indepen-
dently of IL-6 (Figure 6C). Thus, while senescent osteoblasts
can directly stimulate tumor cell growth, possibly adding to the
observed eventual increased tumor burden, IL-6 does not
directly contribute to this increased growth.
Because we failed to show that senescence-derived IL-6
directly stimulated tumor cell growth, we postulated that instead
it played a critical role in senescent-driven increases in local os-
teoclastogenesis that promoted tumor cell seeding. Thus, we
next asked if IL-6 neutralization limited the increased osteoclas-
togenesis we observed near senescent versus non-senescent
osteoblasts. To address this possibility, littermate or FASST
mice were treated with control IgG or a neutralizing IL-6 antibody
prior to the activation of senescence. As expected, treatment
with anti-IL-6 led to a significant reduction in osteoclast surface
area to bone surface area in FASSTmice (Figures 6D andS6E). In
contrast, we did not observe a similar decrease in osteoclast sur-
face area to bone surface when littermate control mice were
treated with neutralizing IL-6 antibody (Figures 6D and S6E).
Given this reduction, we next asked whether osteoclasts directly
near senescent osteoblasts were reduced. As in our previous an-
alyses (Figures 4C–4E), bone sections were stained simulta-
neously to identify senescent (GFP+, OCN+) and non-senescent
(GFP–, OCN+) osteoblasts and TRAP+ osteoclasts.
By utilizing the same statistical analyses for spatial processes
as we did in Figures 4C–4E, we found that osteoclasts localized
near osteoblasts more frequently than chance would predict in
control IgG-treated animals (Figures 6E, upper panel). Further,
this association was significantly (p < 0.0117) increased near se-
nescent versus non-senescent osteoblasts. However, when
mice were treated with anti-IL-6, this increased association
was completely abrogated (p = 1.0) (Figure 6E, lower panel),
Figure 6. Senescent-Derived IL-6 Drives
Increased Osteoclastogenesis and Bone
Metastasis
(A) Quantification of osteoclasts following co-cul-
ture with non-senescent (NS) or senescent (SEN)
osteoblasts in the presence of a control (IgG) or
IL-6-neutralizing antibody (a-IL-6). Bone-marrow-
derived macrophages were cultured with non-se-
nescent or senescent osteoblasts for 4 days in the
presence of 5 pg a-IL-6. The antibody was re-
placed every other day. TRAP staining was carried
out after 4 days co-culture, and osteoclast
numbers were quantitated and are displayed
as TRAP-positive osteoclasts per field of view
(TRAP+OC/FOV) (SEM, *p < 0.05, two-tailed,
Student’s t test; one of two representative exper-
iment is shown).
(B) IL-6-neutralizing antibody reduces bone
metastasis. Littermate (LM) or FASST mice were
treated with 500 mg control antibody (IgG) or IL-6-
neutralizing antibody (a-IL-6) on day 1 and twice
weekly throughout the time course of the experi-
ment. On day 0, NT2.5luc tumor cells were intro-
duced by intracardiac injection. On day 28, mice
were sacrificed, and tumor burden was assessed
by ex vivo imaging of leg bones. Tumor burden is
displayed as photon flux (photons/second) (n > 6,
SEM, *p < 0.05, unpaired Student’s t test).
(C) The growth of NT2.5luc cells was monitored
by bioluminescent imaging in the presence of
conditionedmedium obtained from vehicle (veh) or
4-OHT-treated osteoblasts. Vehicle and 4-OHT-
conditioned medium was treated with either a
control antibody (IgG) or a neutralizing antibody
against IL-6 (a-IL-6). Growth was determined by
the MTT assay (SEM, *p < 0.05, two-tailed, Stu-
dent’s t test; one of two representative experiment
is shown).
(D) Quantification of osteoclast surface area (Oc S)
per bone surface (BS) was carried out on bone
sections obtained from 6-week-old FASST mice
treated with IgG or anti-IL-6 (n = 3 per condition,
SEM, *p < 0.05, two-tailed, Student’s t test).
(E) Computational spatial analysis of bone sec-
tions from FASST mice treated with IgG control
antibody or anti-IL-6 show that anti-IL-6 eliminates
the increased osteoclastogenesis observed locally
around senescent osteoblasts. Mice were treated with IgG or anti-IL-6 2 days before receiving tamoxifen. Mice then received biweekly doses of IgG or anti-IL-6
for 2more weeks before being sacrificed. Statistical analysis of the frequency of senescent versus non-senescent osteoblasts encountering an osteoclast inmice
treated with IgG (upper panel) or anti-IL-6 (lower panel). Data demonstrate a higher association of osteoclasts is observed around senescent osteoblasts in IgG-
treatedmice that is absent in anti-IL-6-treatedmice (n = 3, SEM, *p < 0.05 for IgG-treatedmice and the p value for anti-IL-6 treatedmice was 0.36 [non-significant,
ns], both two-sided Wilcoxon signed-rank test).demonstrating that IL-6 plays a central role in the increased os-
teoclastogenesis observed in our model.
DISCUSSION
The leading cause of cancer-related morbidity and mortality is
metastasis and many solid tumor types metastasize to the
bone. Indeed, nearly 80% of advanced breast cancer patients
develop bone metastases (Coleman and Rubens, 1987).
Growing evidence suggests that systemic effects emanating
from the primary tumor prepare the metastatic niche for tumorcell arrival and survival (Psaila and Lyden, 2009; Sceneay et al.,
2013). While these studies strongly support a role for the primary
tumor in contributing to the development of a metastatic niche,
there has been little investigation into whether local changes
within the bone, independent of the actions of the primary tumor,
contribute to creating a supportive niche. Our studies show that
in the absence of signals emanating from a primary tumor, alter-
ations within the bone niche are sufficient to drive seeding and
growth of disseminated tumor cells.
One strength of ourmodel is themosaic nature of the induction
of senescence, which mirrors that observed in human tissuesCell Reports 14, 82–92, January 5, 2016 ª2016 The Authors 89
including the skin (Dimri et al., 1995). Also, our ability to induce
the phenotype in young mice allowed us to alter the bone envi-
ronment and increase tumor cell seeding within the bone and
metastatic outgrowth. It is important to note that p27Kip1 activa-
tion, while sufficient to induce senescence (Alexander and
Hinds, 2001), has not been implicated in the activation of senes-
cence in humans. In our hands, p27Kip1 functions as a model
that potently activates the SASP and thus has allowed us to
test the role senescent cells and the associated SASP plays in
metastatic seeding and outgrowth in the bone. Using this model,
we show that tumor burdens vary in FASST mice, and this paral-
lels the variable penetrance of senescence (GFP+ cells) activa-
tion we observe in the model. While we are unable to assess
the degree of GFP activation at endpoint in our mice, our tumor
cell seeding data indicate that tumor cells initially localize to
areas where GF, senescent osteoblasts are present. Together
these data support our hypothesis that it is the variable activation
of senescence within individual bones that results in the varied
tumor penetrance.
Our data further define the mechanism that drives the
increased tumor cell seeding in our model. Indeed, we show
that senescent-derived IL-6 drives increases in osteoclasts,
and we postulate that these create active, fertile regions for
disseminated tumor cells to establish metastatic outgrowths.
Thus, IL-6 neutralization in our FASST mice leads to a drastic
reduction in the increased osteoclast surface area to bone sur-
face area (Oc S/BS) and reduced metastatic tumor burden in
the bones. Of note, we see a similar reduction in tumors in litter-
mate mice raising the possibility that IL-6 may function as an
important metastatic driver but may not be senescence specific.
Because disseminated tumor cells do seed into the bones of
littermate mice, albeit at reduced levels compared to FASST
mice and both are blocked by IL-6 neutralization, we postulate
that the appearance of senescent osteoblasts plays a critical
role in metastasis by increasing the productive and fertile seed-
ing areas available to the tumor cells within the bone. Taken
together, these data imply that in our mouse, we have increased
the available fertile seeding areas within the bone by activating
senescence. Thus, it may be in patients that the stochastic na-
ture of stromal-derived alterations increases the probability of
a successful seeding event within the bone.
Our findings have significant implications for how and when
we think about treating patients with early versus late stage dis-
ease. Indeed, our model recapitulates the mosaic appearance of
senescent cells found in human tissues (Dimri et al., 1995). This,
together with our data demonstrating that the stroma is sufficient
to instigate changes that favor tumor cell seeding and growth,
forces us to think about targeting the stromal compartment of
early-stage patients. Current clinical data indicate that breast
cancer cells are present in the circulation as circulating tumor
cells (CTC) and the bone as disseminated tumor cells (DTC) in
many early-stage patients and that the presence of these cells
predicts poor outcome (Hall et al., 2012; Lucci et al., 2012).
Because patients with early-stage disease have primary lesions
that may be too small to elicit systemic effects, the existence of
stromal-initiated changes within the bone could support tumor
CTC and/or DTC cell seeding, survival, and/or growth in the
bone. Accordingly, if senescent stromal cells within the bone in-90 Cell Reports 14, 82–92, January 5, 2016 ª2016 The Authorscrease the number of cancer cells that successfully seed, it is
likely that their presence will negatively impact patient outcome.
Thus, this work highlights the need to understand how stromal-
initiated changes alter the bone niche so that these changes
can be targeted in cancer patients.
EXPERIMENTAL PROCEDURES
Mice Husbandry and Genotyping
All mice were housed in accordance with Washington University in St. Louis’s
Animals Studies Committee. Compound mice contained the pro-alpha 2(I)
collagen gene (Col-Cre-ERT2 mice) (Zheng et al., 2002) and ROSA26 locus
(ROSAlox-stop-lox-p27Kip1) (Lavine et al., 2008). Primer sequences can be
found in the Supplemental Experimental Procedures.
Transgene Activation and Intracardiac Injection
Four-week-old FASST female mice and control littermates were given tamox-
ifen (5 mg/10 g body weight) intraperitoneal (i.p.) administration twice and an
additional dose of tamoxifen at 6 weeks of age. The additional tamoxifen
increased the presence of GFP-positive osteoblasts (Figures S1D–S1F).
10,000 cells/50 ml PBS NT2.5 cells expressing firefly luciferase (NT2.5luc)
were injected directly into the left cardiac ventricle. Bioluminescence imaging
on legs was performed ex vivo 4 weeks later on an IVIS100 or IVIS Lumina (Per-
kinElmer; Living Image 3.2, 1- to 60-s exposures, binning 4, 8, or 16, FOV
15 cm, f/stop1, open filter) following IP injection of D-luciferin (150 mg/kg; Bio-
synth). For analysis, total photon flux (photons/s) was measured from a fixed
region of interest using Living Image 2.6.
Bone Histomorphology and Tartrate-Resistant Acidic Phosphatase
Staining
The tartrate-resistant acidic phosphatase (TRAP) staining was performed on
femur or tibia bones using BioQuant software. Details of areas of interest
can be found in Supplemental Experimental Procedures.
Fluorescence-based TRAP was performed using ELF97 phosphatase sub-
strate Kit (Molecular Probes, E6601; Invitrogen) (Filgueira, 2004) followed by
staining with antibodies against GFP and OCN.
Senescent-Associated b-Galactosidase and Immunofluorescence/
Immunocytochemistry Staining
All SA-b-Gal and immunofluorescence staining were carried out on
cryosections.
Immunofluorescence Staining
anti-GFP (1:1,000, ab13970; Abcam), anti-IL-6 (M-19) (1:50, SC-1265; Santa
Cruz Biotechnology), and anti-OCN (1:50, SC-30045; Santa Cruz Biotech-
nology) were used. Following incubation with primary antibodies, slides were
washed in PBS and incubated for 1 hr with Alexa Fluor secondary antibodies
at room temperature and mounted in ProLong Gold with DAPI antifade
medium.
Luciferase Labeling of NT2.5 Cells and Culture Conditions
Mouse mammary tumor cell line NT2.5 was transduced with a FUW-firefly
luciferase-EGFP (FUW-FFLuc-eGFP) lentiviral construct creating NT2.5luc
cells. To establish the impact of conditioned medium on NT2.5luc cell growth,
conditioned medium was collected from senescent or nonsenescent FASST
osteoblasts, and NT2.5luc cell growth was monitored by luciferase activity.
For IL-6 neutralization experiments, NT2.5luc cells were cultured in the con-
ditioned medium from either senescent or nonsenescent osteoblasts plus
10 pg/ml IL-6 neutralization antibody (catalog no. 554400, BD Biosciences)
or IgG control (catalog no. 40041B, BioLegend). On day 3, NT2.5luc cell growth
was assessed by monitoring luciferase activity.
IL-6 Neutralization in Mice
One day prior to tamoxifen injection FASST or littermate control mice received
either rat anti-murine IL-6 antibody (500 mg/mouse, BioXCell) or rat anti-murine
IgG2a control antibody (500 mg/mouse, BioXCell) via intraperitoneal (i.p.) injec-
tion. Mice continued to receive additional antibody twice a week until sacrifice.
Image Acquisition
Images were acquired using a Nikon Eclipse Ti-E microscope. Details for the
osteoclast-osteoblast and senescent osteoblast-tumor spatial analysis cell
can be found in Supplemental Experimental Procedures.
Cell Culture
Primary osteoblastswere grown in the culturemedium (CM), ascorbic acid free
alpha-MEM (catalog no. A10490, Invitrogen), containing 10% fetal bovine
serum (FBS) (catalog no. SH30109.03, Thermo Scientific) and antibiotics
(100 U/ml of penicillin and 100 mg/ml of streptomycin, catalog no. P0781,
Sigma). To study the differentiation ability of senescent osteoblasts, cells
weremaintained in osteogenicmedium (OM) consisting of alpha-MEM supple-
mented with 10% FBS, 50 mg/ml ascorbic acid (catalog no. A4544, Sigma),
and 10 mM b-glycerophosphate (catalog no. G9422, Sigma). Bone marrow
macrophages were cultured in alpha-MEM (catalog no. 12561, Invitrogen)
containing 10%FBS (catalog no. 26140-079, Invitrogen) and 10%CMGsuper-
natant kindly provided by D.V.N., which was made as described previously
(McHugh et al., 2000). 293T cells were cultured in DMEM with 10% FBS (cat-
alog no. F2442, Sigma) and antibiotics.
Primary Osteoblasts Isolation, Viral Transduction, and Senescence
Induction
Primary osteoblasts were isolated from the long bones as described previ-
ously (Bakker and Klein-Nulend, 2012).
Primary osteoblasts isolated from the FASST p27(+/+) mice were infected
with pMSCVCre-ERpuro retrovirus. To activate the p27 transgene, stably
transduced osteoblasts were treated with 10 mM Tamoxifen (13258, Cayman
Chemical Company) or vehicle control for 3 days and then stained for senes-
cence-associated b-galactosidase activity as previously described (Pazolli
et al., 2009). Osteoblasts were consistently maintained at 3% O2 at 37
C.
mRNA Isolation and qRT-PCR
Total RNA was isolated from primary osteoblasts using the Ambion RiboPure
RNA isolation kit (AM1924, Invitrogen) according to the manufacturer’s in-
structions. For cDNA synthesis, 1 mg of RNA was reverse-transcribed using
SuperScript II (18064-014, Invitrogen) according to themanufacturer’s instruc-
tions. The qPCR was performed using a CFX96 Real-Time system (Bio-Rad)
and TaqMan gene expression assays for IL-6, ALP RANKL, and OPG. GAPDH
was used as the endogenous control (Invitrogen). To establish the impact of
IL-6 neutralization on IL-6 expression, 10 pg/ml of an IL-6 neutralization anti-
body (catalog no. 554400, BD Biosciences) or IgG control (catalog no.
40041B, BioLegend) was added to the senescent osteoblasts for 4 days,
and SASP expression was analyzed by RT-PCR.
Osteoblast Differentiation Assays
To assess differentiation, 1 3 105 osteoblasts/well were plated onto 6-well
plates in culture medium (CM). The following day medium was replaced with
osteogenic medium, which was refreshed every 3 days. RNA isolation and
alkaline phosphatase staining was carried out on day 7, and alizarin red S
staining was carried out on day 21.
Alkaline phosphatase staining was performed as previously described (Ka-
tagiri et al., 1994). For alizarin red S staining, osteoblasts were fixed in 70%
ethanol for 1 hr, rinsed with water, and stained with 0.4% alizarin red S
(A5533, Sigma) (pH 4.1–4.3) for 10 min at room temperature.
Bone Marrow Macrophage Isolation and Osteoblast-BMM Co-
culture Assay
Bone marrow macrophage (BMM) were obtained from 6-week-old mice. For
the co-culture assay, 2 3 104 senescent versus control osteoblasts and 1 3
105 BMMs/well were plated into 24-well plates with 10 nM 1,25(OH)2 VitD3
(D1530, Sigma) and 100 nM dexamethasone (D4902, Sigma). The cells were
co-cultured for 4 days and then stained for tartrate-resistant acid phosphatase
activity using the Acid Phosphatase, Leukocyte (TRAP) kit (387A, Sigma) ac-
cording to themanufacturer’s instructions. For IL-6 neutralization in this assay,senescent or non-senescent osteoblasts were co-cultured with BMMs, and
5 pg/ml of IL-6 neutralization antibody (catalog no. 554400, BD Biosciences)
or 5 pg/ml of IgG control (catalog no. 40041B, BioLegend) was added to the
medium. The antibody was replenished every other day, and mature osteo-
clasts formation was detected by TRAP staining on day 4.
Statistical Analyses
All statistical analyses were carried out using GraphPad prism. Numerical data
are expressed as mean ± SEM. Mouse analyses were performed by Student’s
t test or Mann-Whitney test as indicated in the figure legends. Description of
statistical analyses used in bone analysis of osteoclastogenesis and tumor
localization can be found in the description of the computational approach
in Experimental Procedures.
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